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CC BY-NC-ND license (http://creativeBackground: The epidemiology of pyogenic liver abscess continues to change and the issue of
antimicrobial therapy is controversial. This study investigated the epidemiology and clinical
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Methods: The annual incidence rates, demographic data, underlying diseases, complications,
length of stay, mortality rates, and antimicrobial therapy were analyzed using the data
retrieved from the Longitudinal Health Insurance Database 2000, Taiwan, from 2000 to 2011.
Results: The annual incidence of pyogenic liver abscess for all age groups increased gradually
in Taiwan from 10.83 per 100,000 person-years in 2000 to 15.45 per 100,000 person-years in
2011. Pyogenic liver abscess occurred more commonly in patients with male sex, of older
age (>50 years), and lower family income. Among the 1522 adult patients with pyogenic liver
abscess, 537 (35.3%) patients had diabetes mellitus, 165 (10.8%) patients had complications,
234 (15.4%) patients received mechanical ventilation, and 361 (23.7%) patients had a stay in
intensive care; the mortality rate was 8.2% (125/1522). There were 426 (28%) patients treated
with cefazolin and 158 (10.4%) patients treated with extended-spectrum cephalosporins.
There were no statistically significant differences in the length of stay and mortality rates be-
tween these two groups (20.2 days vs. 23.1 days; and 7.5% vs. 10.1%, respectively).
Conclusion: The clinical outcomes of pyogenic liver abscess treated with cefazolin werenfectious Diseases, Taichung Veterans General Hospital, Number 1650, Section 4, Taiwan Boulevard,
.tw, secretwizard@gmail.com (Z.-Y. Shi).
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Analysis of liver abscess in Taiwan 647comparable to those treated by extended-spectrum cephalosporins. Extended-spectrum ceph-
alosporins should be used for severe complications, such as meningitis and endophthalmitis.
Further surveillance of epidemiology and cohort analysis of antimicrobial therapy are impor-
tant.
Copyright ª 2014, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).Introduction
Pyogenic liver abscess is usually a complication of biliary
tract disease, and Escherichia coli is the most common
pathogen of liver abscess in the world.1e3 Liver abscess in
Taiwan is caused mainly (w69e78%) by Klebsiella pneu-
moniae,4,5 and has become an endemic disease during the
past 3 decades since the first publication in Taiwan in
1986.1,6e8 K. pneumoniae liver abscess is characterized by
the high rates of metastatic infections (9.5e20.0%)1,7,8 and
mortality (6.0e11.3%),8e10 and an association with diabetes
mellitus (DM) (56.8e75.0%).1,4,8
A nationwide analysis of pyogenic liver abscess from the
National Health Insurance Research Database (NHIRD) from
1996 through 2004 was published in 2008.11 The annual
incidence of pyogenic liver abscess increased from 11.15/
100,000 population in 1996 to 17.59/100,000 population in
2004.11 The population-based abscess-related death
increased slightly from 1.38/100,000 in 1996 to 1.80/
100,000 in 2004.11 There were 33.3% (9904/29,703) of pa-
tients with pyogenic liver abscess had DM.
Patients with liver abscess treated with cefazolin had a
greater chance of developing complications (22/59, 37.3%)
than those receiving extended-spectrum cephalosporins (3/
48, 6.3%) (p < 0.001) in a previous study.12 Four (4.3%)
patients from the group who were treated with cefazolin
had metastatic infections in another study.10 The limita-
tions of these two studies were that they did not include a
sufficient number of patients to be stratified by severity of
infection and to evaluate the clinical efficacy. More large-
scale studies are needed to determine whether extended-
spectrum cephalosporins are superior to cefazolin.
The trends in the epidemiology of pyogenic liver abscess
have changed gradually over the past 3 decades and anti-
microbial therapy strategy remains in debate. This study
was therefore conducted to evaluate the trend in epide-
miology changes and to compare the clinical outcomes
between two groups of patients treated with cefazolin or
extended-spectrum cephalosporins by an analysis of the
data retrieved from NHIRD, Taiwan, from 2000 to 2011.
Methods
Data sources: The National Health Insurance
Research Database and Longitudinal Health
Insurance Database 2000
The data used in this study were retrieved from the Longitu-
dinal Health Insurance Database 2000 (LHID 2000) for the
period of 2000e2011. LHID 2000 contains the reimbursementclaims data of 1,000,000 beneficiaries, randomly sampled
from the year 2000 Registry for Beneficiaries (n Z 23.75
million) of the NHIRD. The NHIRD is managed and updated
annually by the National Health Research Institute. The
updated data in the NHIRD were provided by the Bureau of
National Health Insurance, Department of Health, Taiwan.
Annual incidence and mortality
To avoid duplicate calculation due to transfer of patients
between hospitals, only those newly-diagnosed patients
who were hospitalized for pyogenic liver abscess for the
first time were included for the calculation of incidence
rate. The annual incidence rate of pyogenic liver abscess
was defined as the number of newly-diagnosed patients
with pyogenic liver abscess divided by the number of citi-
zens in Taiwan in that year. The annual incidence rate
included patients from all age groups. For the analysis of
antimicrobial therapy, the adult patients with liver abscess
were selected using the following two criteria: adult pa-
tients, 20 years old, admitted with a diagnosis of pyogenic
liver abscess from January 1, 2000 to December 31, 2011;
and a discharge diagnosis of ICD-9-CM 572.0 (abscess of the
liver). Diagnoses of amebic liver abscess (ICD-9-CM 006.3)
and injury to the liver (ICD-9-CM 864.00eICD-9-CM 864.19)
were excluded.
Hospital mortality was defined as death occurring in
hospital or within 30 days after discharge.
Demographic variables
The following demographic characteristics of patients with
liver abscess were analyzed. The ages were categorized into
six groups: 20e29 years, 30e39 years, 40e49 years,
50e59 years, 60e69 years, and 70 years. Urbanization of
Taiwan was classified into four levels: 1 indicates the highest
level of urbanization and 4 represents the lowest. Family in-
come was ranked into four levels (in New Taiwan Dollars,
NTD): 0, 1e15,840, 15,841e28,800, 28,801e45,800, and
45,801. Geographic areas of Taiwan were classified into
northern, central, southern, and eastern. Occupations were
divided into public and military, industry, business, low in-
come, and others (including the retired).
Definition of comorbidities, complications, and
antimicrobial therapy
The following comorbidities were analyzed: DM (ICD-9-CM
250), cirrhosis (ICD-9-CM 571.0e571.3, 571.5, and 571.6),
cholelithiasis (ICD-9-CM 574), viral hepatitis including
Table 1 The annual incidence and mortality of pyogenic
liver abscess during the period 2000e2011 from the Longi-
tudinal Health Insurance Database 2000, Taiwan
All ages Adults
Year N Incidencea N Incidencea Deaths
2000 107 10.83 105 14.82 13
2001 110 11.26 108 14.89 17
2002 136 14.07 135 18.14 12
2003 103 10.73 103 13.50 8
2004 136 14.26 135 17.33 12
2005 121 12.77 120 15.13 13
2006 148 15.73 146 18.12 7
2007 133 14.24 133 16.25 10
2008 123 13.27 122 14.67 9
2009 140 15.23 140 16.56 10
2010 135 14.80 135 15.72 5
2011 140 15.45 140 16.03 9
1532b 13.52c 1522b 15.94c 125d
a Number per 100,000 person-years.
b Total number of patients with pyogenic liver abscess.
c Average annual incidence.
d Total number of deaths.
648 Y.-C. Chen et al.hepatitis B (ICD-9-CM 070.2, 070.3, and V02.61) and hepa-
titis C (ICD-9-CM 070.41, 070.44, 070.51, 070.54, and
V02.62), renal disease (ICD-9-CM 585 and 593.9), hepato-
cellular carcinoma (ICD-9-CM 155.0 and 155.2), other ma-
lignancies (ICD-9-CM 140e208.91) that exclude metastatic
cancers (ICD-9-CM 196e199), and malignant neoplasms of
ill-defined sites (ICD-9-CM 195).
The following infections related to liver abscess were
defined as complications: endophthalmitis (ICD-9-CM 360.0),
brain abscess (ICD-9-CM 324.0), intraspinal abscess (ICD-9-
CM 324.1), bacterial meningitis (ICD-9-CM 320), lung abscess
(ICD-9-CM 513), pneumonia (ICD-9-CM 480e486), acute res-
piratory distress syndrome (ICD-9-CM 518.5), osteomyelitis
(ICD-9-CM 730), and abscess of the prostate (ICD-9-CM 601.0,
601.2, 601.8, and 601.9) during hospitalization.
The data relating to antimicrobial agents were retrieved
fromthe LHID 2000 using the codes of the antibiotics from the
National Health Insurance Administration Ministry of Health
and Welfare website (http://www.nhi.gov.tw). Four groups
of antimicrobial therapy were identified, i.e., cefazolin,
extended-spectrum cephalosporins, cefazolin*extended-
spectrum cephalosporins, and other antimicrobial agents.
Cefazolin*extended-spectrum cephalosporins was used in
the following two situations: cefazolin was used first as
empiric therapy and then transited to extended-spectrum
cephalosporins, or vice versa. The clinical outcomes be-
tween these four groups of patients were compared. The
extended-spectrum cephalosporins included ceftriaxone,
cefotaxime, ceftazidime, cefoperazone, and flomoxef.
There were no available Acute Physiology, Age, Chronic
Health Evaluation (APACHE) data in the NHIRD. The following
three severe conditions of infection, i.e., complications,
mechanic ventilation, and intensive care unit (ICU) stay,
were therefore used instead to provide the risk stratification
for severely ill hospitalized patients.
Statistical analysis
Student t test and analysis of variance were used for the
analysis of continuous variables. Categorical data were
compared by Chi-square test or Fisher’s exact test. A
p < 0.05 was considered to be statistically significant. All
analyses were performed by SAS statistical software for
Windows (version 9.3; SAS Institute, Inc., Cary, NC, USA).
Results
The annual incidence rates from 2000 to 2011 are shown in
Table 1 and Fig. 1. The annual incidence of pyogenic liver
abscess for all age groups increased gradually in Taiwan
from 10.83 per 100,000 person-years in 2000 to 15.45 per
100,000 person-years in 2011. The average annual inci-
dence of all age groups was 13.52 per 100,000 person-years
during the period 2000e2011.
A total of 1522 adult patients with pyogenic liver abscess
met the inclusion criteria and were enrolled in this study.
The annual incidence of pyogenic liver abscess (for patients
aged > 20 years) increased gradually from 14.82 per
100,000 person-years in 2000 to 16.03 per 100,000 person-
years in 2011. The average annual incidence of patients
>20 years was 14.59 per 100,000 person-years during theperiod of 2000e2011. There were only 10 patients with
pyogenic liver abscess aged <20 years during the period
being studied.
Table 2 shows the demographic characteristics of 1522
adult patients with newly-diagnosed liver abscesses. There
were more men (63.6%) than woman (36.4%). The age at
presentation ranged from 20.1 years to 96.1 years, with a
mean age of 61.0  15.1 years. It is worth noting that 76.8%
of patients were S50 years old. The percentages of ur-
banization levels from 1 to 4 were 27.8%, 28.1%, 15.4%, and
28.6%, respectively. Patients with a family income of new
NTD 15,841e28,800 accounted for the highest percentage
(45.6%) of patients with pyogenic liver abscess. The per-
centages of patients with liver abscess in the northern
(47.6%) and southern (30.9%) areas were greater than those
in other geographic locations. Industry (43.2%) and business
(26.0%) were the two most common occupations.
Table 3 shows the clinical characteristics of 1522 adult
patients with liver abscess during the period 2000e2011.
Among these individuals, the three most common underly-
ing diseases were DM (35.3%), cholelithiasis (13.1%), and
hepatocellular carcinoma (9.8%). Of the 1522 patients, 165
(10.8%) developed complications, 234 (15.4%) received
mechanical ventilation, and 361 (23.7%) stayed in the ICU,
with an average stay of 9.03  12.5 days. The average
length of stay in hospital (ALOS) was 20.9  23.3 days.
There were 596 (39.2%) patients with a length of stay (LOS)
of 14 days, 646 (42.4%) patients with LOS of 15e28 days,
and 280 (18.4%) patients with a LOS of 29 days. There
were 426 (28.0%) patients treated with cefazolin and 158
(10.4%) were treated with extended-spectrum cephalo-
sporins. The mortality rate was 8.2% (125/1522).
Among the 426 patients in the group treated with cefa-
zolin, there were 25 (5.9%) patients with pneumonia, three
(0.7%) patients with endophthalmitis, and one (0.2%) pa-
tient with meningitis. Among the 158 patients in the group
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Figure 1. The incidence of pyogenic liver abscess per 100,000 population according to the Taiwan National Health Insurance
Database during the period 2000e2011 (the Longitudinal Health Insurance Database 2000). The cases exclude individuals <20 years
old.
Analysis of liver abscess in Taiwan 649treated with extended-spectrum cephalosporins, 27 (17.1%)
had pneumonia, four (2.5%) had endophthalmitis and one
(0.2%) had meningitis. Of the 79 patients treated with
cefazolin*extended-spectrum cephalosporins, eight (10.1%)
had pneumonia and five (6.3%) had endophthalmitis.
Table 4 compares the severity and clinical outcomes
among the three groups of patients in the study. The
complication rate of the 426 patients treated with cefazolin
was lower than that of the 158 patients treated with
extended-spectrum cephalosporins (8.0% vs. 20.9%,
p < 0.001). There was no statistically significant difference
in the use of mechanical ventilation between these two
groups (14.6% vs. 20.9%, p Z 0.065). The patients treated
with cefazolin had a lower rate of ICU stay than those
treated with extended-spectrum cephalosporins (18.3% vs.
37.3%, p < 0.001).
Although there was a statistically significant difference
in the LOS among these three groups (pZ 0.004), there was
no significant difference in the LOS between the groups
treated with cefazolin and extended-spectrum cephalo-
sporins (20.2  30.9 days vs. 23.1  19.7 days). There was
no significant difference in the mortality of these two
groups of patients.
Table 5 lists the clinical outcomes of patients in the
groups treated with cefazolin and extended-spectrum
cephalosporins that had severe infections, including com-
plications, mechanical ventilation, and ICU stay. Among the
67 patients with complications, 34 (50.7%) were treated
with cefazolin and 33 (49.3%) were treated with extended-
spectrum cephalosporin. There were no statistically sig-
nificant differences in the ALOS (42.6  100.0 days vs.
30.6  29.8 days, p Z 0.508) and mortality (20.6% vs.
18.2%, pZ 0.803) between these two groups. Among the 95
patients who received mechanical ventilation, 62 (65.3%)were treated with cefazolin and 33 (34.7%) with extended-
spectrum cephalosporin. These two groups had no statisti-
cally significant differences in the ALOS (32.2  74.8 days
vs. 30.9  31.5 days, p Z 0.907) or mortality (24.2% vs.
33.3%, p Z 0.341). Of the 137 patients who had been
admitted to ICU, 78 (56.9%) received cefazolin and 59
(43.1%) received extended-spectrum cephalosporin. There
were no statistically significant differences in the ALOS
(20.2  14.1 days vs. 26.5  25.4 days, p Z 0.091) and
mortality rate (24.4% vs. 20.3%, p Z 0.578) of the two
groups.Discussion
In this study, the annual incidence of pyogenic liver abscess
increased gradually in Taiwan from 10.83 per 100,000
person-years in 2000 to 15.45 per 100,000 person-years in
2011. The annual incidence rates of this disease are low in
other countries, being 2.3 per 100,000 person-years in
Canada from 1999 to 2003 according to population-based
surveillance, for example.13 In a nationwide study spanning
a 26-year period in Denmark, the annual incidence rate of
pyogenic liver abscess was 1.1 per 100,000 person-years
from 1997 to 2002.14. The incidence of pyogenic liver ab-
scess is much higher in Taiwan, which could be due to the
spread of a pathogenic clone.1 It has become an emerging
infectious disease in Japan, Korea, and the United
States.15e19 How these international pathogenic clones are
related remains to be clarified by molecular typing
methods.
From the demographic data, there appear to be several
variables that could increase the risk of developing pyo-
genic liver abscess. First, more males than females (63.6%
Table 2 Demographic data of 1522 patients with pyogenic
liver abscess during the period 2000e2011 from the Longi-
tudinal Health Insurance Database 2000, Taiwan
Sex, n (%)
Female 554 (36.4)
Male 968 (63.6)
Age, y
Mean (SD) 61.0 (15.1)
Range (median) 20.1e96.1 (61.5)
20e29 42 (2.8)
30e39 99 (6.5)
40e49 211 (13.9)
50e59 366 (24.0)
60e69 320 (21.0)
70 484 (31.8)
Urbanizationa
1 418 (27.8)
2 422 (28.1)
3 232 (15.4)
4 430 (28.6)
Family income (NTDb)
0 234 (15.5)
1e15,840 346 (22.7)
15,841e28,800 694 (45.6)
28,801e45,800 162 (10.6)
45,801 86 (5.7)
Area
Northern 725 (47.6)
Central 288 (18.9)
Southern 471 (30.9)
Eastern 38 (2.5)
Occupation
Public and military 97 (7.3)
Industry 577 (43.2)
Business 348 (26.0)
Low income 17 (1.3)
Others and retired 298 (22.3)
a Urbanization level: 1 indicates the highest level of urbani-
zation and 4 the lowest.
b NTD Z New Taiwan dollar.
Table 3 Clinical characteristics of 1522 patients with
pyogenic liver abscess during the period 2000e2011 from
the Longitudinal Health Insurance Database 2000, Taiwan
Clinical characteristics n (%)
Underlying diseases
Diabetes mellitus 537 (35.3)
Cirrhosis 99 (6.5)
Cholelithiasis 199 (13.1)
Viral hepatitis 93 (6.1)
Renal disease 26 (1.7)
Hepatocellular carcinoma 149 (9.8)
Other malignancies 83 (5.5)
Complications 165 (10.8)
Mechanical ventilation 234 (15.4)
Intensive care unit (ICU) stay 361 (23.7)
Length of ICU staya 9.03  12.5
Length of staya 20.9  23.3
Number of patients grouped by length of stay
14 d 596 (39.2)
15e28 d 646 (42.4)
>28 d 280 (18.4)
Mortality 125 (8.2)
Antimicrobial therapy
Cefazolin 426 (28.0)
Extended-spectrum cephalosporins 158 (10.4)
Cefazolin and extended-spectrum 79 (5.2)
Other 859 (56.4)
a Mean  standard deviation, days.
650 Y.-C. Chen et al.vs. 36.4%) had such an abscess. Second, the incidence
increased with age. Pyogenic liver abscess rarely occurred
in children and adolescents; patients aged >50 years
accounted for 76.8%. It is reasonable to assume that the
elderly may have more comorbidities that predispose to
pyogenic liver abscess. Third, pyogenic liver abscess
occurred more commonly in patients with a lower monthly
income. Patients with a monthly family income < NTD
28,800 accounted for 83.8% of patients with pyogenic liver
abscess. Fourth, industry and business were the two most
common occupations among patients with pyogenic liver
abscess.
According to a number of studies, about 56.8e75.0% of
patients with K. pneumoniae liver abscess had DM, and DM
was considered a risk factor of this disease.1,4,8 These are
small-scale hospital-based studies, however, which could
not reflect the exact percentage of DM. In the current
study, the percentage of patients with DM was only 35.3%.
This is similar to the finding of a recent study that retrieveddata from the NHIRD, which showed that the percentage of
DM in patients with pyogenic liver abscess was 33.3%.11 In
this study, 9.8% of patients with pyogenic liver abscess had
hepatocellular carcinoma. In a population-based study
using data from the NHIRD, the incidence of gastrointes-
tinal cancer was 4.3-fold higher among patients with pyo-
genic liver abscess compared with controls (10.8/1000
person-years vs. 2.51/1000 person-years).20 Similarly,
another survey from the NHIRD reported that individuals
with pyogenic liver abscess had a higher risk of liver cancer,
biliary tract cancer, and colorectal cancer.21 According to
these large-scale population-based surveys, the evaluation
of pyogenic liver abscess patients for hepatocellular cancer
and colorectal cancer is an important new issue.
From population-based data from the NHIRD during the
period 2000e2004,11 of the 13,672 patients with pyogenic
liver abscess, 155 (1.1%) had meningitis, 226 (1.7%) had
endophthalmitis, 1141 (8.3%) had pneumonia, and 3252
(23.8%) had sepsis. Binary logistic regression analysis from
the NHIRD from 1996 to 2004 found that underlying renal
disease (odds ratio 2.45, 95% confidence interval
2.181e2.756; p < 0.001) and malignancy (odds ratio 2.136,
95% confidence interval 1.859e2.454; p < 0.001) increased
the incidence and mortality rates of pyogenic liver
abscess.11
Pyogenic liver abscess is a relatively common disease in
Taiwan. It is well known that it should be treated by
cephalosporin rather than carbapenem or fluoroquinolone;
however, many patients cannot tolerate the adverse ef-
fects.8,10,12 The clinical outcomes of treatment with
Table 4 Comparison of severity and clinical outcomes among three treatment groups
Clinical characteristics Cephalosporins p
Cefazolin
(n Z 426)
Extended-spectrum
(n Z 158)
Cefazolin*extended-spectrum
cephalosporins (n Z 79)
n (%) n (%) n (%)
Complications 34 (8.0) 33 (20.9) 15 (19.0) <0.001a
Mechanical ventilation 62 (14.6) 33 (20.9) 20 (25.3) 0.027a
Intensive care unit (ICU) stay 78 (18.3) 59 (37.3) 30 (38.0) <0.001a
Length of ICU stayb 6.13  6.65 10.3  15.0 10.1  11.8 0.061c
Length of stayb 20.2  30.9 23.1  19.7 31.3  21.9 0.004c,d
Number of patients grouped by length of stay <0.001a
14 days 172 (40.4) 58 (36.7) 10 (12.7)
15e28 days 185 (43.4) 65 (41.1) 39 (49.4)
>28 days 69 (16.2) 35 (22.2) 30 (38.0)
Mortality 32 (7.5) 16 (10.1) 10 (12.7) 0.259a
a p value was analyzed by Chi-square test.
b Mean  SD, days.
c Analysis of variance.
d Difference between cefazolin group and cefazolin*extended-spectrum cephalosporin groups.
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receiving extended-spectrum cephalosporins in this study.
There were, however, 859 (56.4%) patients treated with
other antimicrobial agents. There were several reasons for
this finding, such as the preference for using carbapenem
for sepsis, intolerance to adverse effects, superinfectionTable 5 Comparison of clinical outcomes between two treat
(stratified by complications, mechanical ventilation, and intensiv
Basal characteristic
Cefazolin
n (%)
Complications 34
Length of stay, mean  SD, d 42.6  100.0
Number of patients grouped by LOS
14 d 9 (26.5)
15e28 d 11 (32.4)
>28 d 14 (41.2)
Mortality 7 (20.6)
Mechanical ventilation 62
Length of stay, mean  SD, d 32.2  74.8
Number of patients grouped by LOS
14 d 19 (30.7)
15e28 d 23 (37.1)
>28 d 20 (32.3)
Mortality 15 (24.2)
ICU stay, number of patients 78
Length of stay, mean  SD, d 20.2  14.1
Number of patients grouped by LOS
14 d 30 (38.5)
15e28 d 32 (41.0)
>28 d 16 (20.5)
Mortality 19 (24.4)
a Student t test.
b Chi-square test.
ICUZ intensive care unit; LOSZ length of stay; SDZ standard deviatwith Enterobacteriaceae, resistance to cephalosporins,
etc. We were unable to analyze these reasons by this
retrospective study. The severe complications (such as
infection of central nervous system, endophthalmitis, or
superinfection by resistant microorganisms) should be
treated by extended-spectrum cephalosporins, because ofment groups in patients with severe pyogenic liver abscess
e care unit stay)
Cephalosporin p
Extended-spectrum
n (%)
33
30.6  29.8 0.508a
0.802b
10 (30.3)
12 (36.4)
11 (33.3)
6 (18.2) 0.803b
33
30.9  31.5 0.907a
0.931b
11 (33.3)
11 (33.3)
11 (33.3)
11 (33.3) 0.341b
59
26.5  25.4 0.091a
0.536b
18 (30.5)
25 (42.4)
16 (27.1)
12 (20.3) 0.578b
ion.
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This is well known by physicians of internal medicine and
the use of cefazolin for the aforementioned condition is
rare.
There were no statistically significant differences in the
length of stay and mortality rates between the groups
treated with cefazolin and extended-spectrum cephalo-
sporins (20.2 days vs. 23.1 days; 7.5% vs. 10.1%, respec-
tively). It was possible that patients with mild infections
were treated with cefazolin and patients with severe in-
fections were treated with extended-spectrum cephalo-
sporins. However, even for the patients with severe
infections, complications, mechanical ventilation, and ICU
stay there were no significant differences in the length of
stay and mortality rates. We should be cautious when
interpreting this finding because this retrospective study
did not stratify the severity of complications. Prospective
randomized, controlled clinical trials are needed to clarify
the optimal antimicrobial strategy for pyogenic live abscess
in individuals with severe complications.
The overall mortality rate (8.2%) in this study was
comparable to those (6e11.3%) of previous hospital-based
studies8e10 and that (10.3%) of a population-based study.11
The complication rate (10.8%) in this study was comparable
to those (9.5e20%) of previous hospital-based studies.1,7,8
A previous report showed that patients receiving cefa-
zolin treatment had a significantly higher likelihood of
developing severe complications than those on extended-
spectrum cephalosporin treatment (37% vs. 6.3%,
p < 0.001).12 By contrast, low rates of metastatic infections
(4.3%), complications (septic shock 1.1%, acute respiratory
failure 3.3%), and mortality (5.4%) for patients treated with
cefazolin and aminoglycosides for > 3 days were shown in
another study.10 The majority (76.5%) of metastatic in-
fections occurred within the first 3 days after presentation,
so they could not be attributed to treatment. The authors
therefore recommend that extended-spectrum cephalo-
sporins be targeted to patients with high risk factors for the
occurrence of metastatic infections. Further large-scale
control studies are needed to clarify the clinical out-
comes of different treatment strategies.
There were some limitations in this study. First, because
the data were sourced retrospectively from the NHIRD, the
detailed data of severity of underlying diseases for each
patient were lacking. We were unable to stratify the risk
factors by APACHE score or determine the causes of death,
such as inadequate drainage, comorbidities, complications,
superinfection, etc. Second, there was only the expendi-
ture on each antimicrobial agent available rather than
dosage regimens or date of therapy in the NHIRD. We were
therefore unable to analyze the duration and sequence of
therapy for each antimicrobial agent. Third, the data from
treatment groups were not stratified by combination of
aminoglycosides, therefore the in vivo synergistic effect
was unknown. Fourth, there were no microbiological data
available in the NHIRD, therefore we were unable to
analyze the clinical outcome of treatment for a single
pathogen.
In conclusion, the clinical outcomes of pyogenic liver
abscess treated with cefazolin were comparable to those
treated by extended-spectrum cephalosporins. However,
extended-spectrum cephalosporins should be used forsevere complications, such as infection of central nervous
system and endophthalmitis. Further surveillance of inci-
dence, investigation of risk factors, and cohort analysis of
antimicrobial therapy are important issues for this disease.Conflicts of interest
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